Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Esperion Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 0ET's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 0ET underperformed the German Biotechs industry which returned -5.4% over the past year.
Return vs Market: 0ET exceeded the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Esperion Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 0ET (€32.47) is trading below our estimate of fair value (€134.06)
Significantly Below Fair Value: 0ET is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 0ET is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 0ET is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 0ET's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 0ET is overvalued based on its PB Ratio (48.6x) compared to the DE Biotechs industry average (3.6x).
How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0ET is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0ET is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0ET is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0ET's revenue (28% per year) is forecast to grow faster than the German market (4.2% per year).
High Growth Revenue: 0ET's revenue (28% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0ET's Return on Equity is forecast to be very high in 3 years time (421.4%).
How has Esperion Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 0ET is currently unprofitable.
Growing Profit Margin: 0ET is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 0ET is unprofitable, and losses have increased over the past 5 years at a rate of -21.7% per year.
Accelerating Growth: Unable to compare 0ET's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0ET is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: 0ET has a negative Return on Equity (-487.04%), as it is currently unprofitable.
How is Esperion Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 0ET's short term assets ($211.7M) exceed its short term liabilities ($66.1M).
Long Term Liabilities: 0ET's short term assets ($211.7M) exceed its long term liabilities ($128.4M).
Debt to Equity History and Analysis
Debt Level: 0ET's debt to equity ratio (664.4%) is considered high.
Reducing Debt: 0ET's debt to equity ratio has increased from 3.6% to 664.4% over the past 5 years.
Inventory Level: 0ET has a low level of unsold assets or inventory.
Debt Coverage by Assets: 0ET's debt is covered by short term assets (assets are 1.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0ET has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0ET has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -21.4% each year.
What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 0ET's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 0ET's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 0ET's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 0ET's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 0ET's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Mayleben (58yo)
Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD9.72M) is above average for companies of similar size in the German market ($USD1.36M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
|CFO & Corporate Secretary||2.17yrs||US$2.54m||0.068% $594.3k|
|Chief Commercial Officer||1.92yrs||US$9.12m||0.094% $825.1k|
|Chief Technical Operations Officer||0.50yr||no data||no data|
|Senior Director of Investor Relations||1.83yrs||no data||no data|
|Chief Ethics & Compliance Officer||0.67yr||no data||no data|
|Vice President of Corporate Development & Strategy||no data||no data||no data|
|Head of Marketing||no data||no data||no data|
|Chief Development Officer||1.92yrs||no data||0.020% $175.0k|
|Senior Vice President of Clinical Development||1.92yrs||no data||no data|
Experienced Management: 0ET's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
|Independent Director||7.33yrs||US$270.58k||0.018% $158.1k|
|Lead Independent Director||4.25yrs||US$311.66k||0.030% $264.8k|
|Independent Non-Employee Director||no data||no data||0.0024% $20.8k|
|Independent Director||6.17yrs||US$290.84k||0.018% $158.1k|
|Independent Director||1.83yrs||US$477.34k||0.018% $158.1k|
|Director||0.83yr||no data||0.036% $316.2k|
|Independent Director||6.08yrs||US$287.35k||0.036% $317.3k|
Experienced Board: 0ET's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 0ET insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Esperion Therapeutics, Inc.
- Ticker: 0ET
- Exchange: DB
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$970.914m
- Listing Market Cap: US$875.667m
- Shares outstanding: 27.51m
- Website: https://www.esperion.com
Number of Employees
- Esperion Therapeutics, Inc.
- 3891 Ranchero Drive
- Suite 150
- Ann Arbor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ESPR||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 2013|
|0ET||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2013|
|0IIM||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jun 2013|
|0ET||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Jun 2013|
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/27 23:41|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.